BRII-196/BRII-198 for Coronavirus (TICO Trial)

"This study is no longer recruiting patients for participation. The trial was originally posted on August 4th, 2020 and was last updated on August 26th, 2020. However, there are 1134 other studies actively recruiting patients with covid-19 and 18 trials for BRII-196/BRII-198 that are still enrolling participants."

"Patients with a spo2 level at or below 94%, who are currently hospitalized, and have been diagnosed with coronavirus disease 2019 may be eligible to receive BRII-196/BRII-198."

"BRII-196/BRII-198 was first studied in 2020 at Island Health - Victoria General Hospital. There have been a total of 18316 completed studies as of now. Additionally, there are 18 live studies being conducted with many of them taking place in Winston-Salem, North carolina."

"There are 100 total sites for this trial, with locations including UCSF Medical Center at Mount Zion (Site 203-007), 1600 Divisadero St. in Winston-Salem, Wake Forest University Health Sciences (Site 210-001), Medical Center Blvd in Pittsburgh, and UPMC Presbyterian Hospital (Site 209-001), 200 Lothrop Street in Roanoke, among others."

"BRII-196/BRII-198 has been given a safety rating of 3. This is based off the fact that it is currently in Phase 3 trials, which suggests that not only does this medication show some efficacy, but also that there are multiple rounds of data supporting its safety."

"This study is not currently looking for new patients, as evident from the clinicaltrials.gov listing which was last updated on 8/26/2022. Although this trial isn't enrolling, there are 1,152 other trials that are still recruiting patients."

"There are 442 cities and 40 countries with ongoing clinical trials for BRII-196/BRII-198. The first study, which was sponsored by AbbVie in 2020, completed Phase 3 drug approval after 2900 patients were enrolled. In the two years since, a total of 18316 studies have been conducted."